The Crimean Congo Hemorrhagic Fever European Consortium: Modern Approaches to Diagnostics, Epidemiology, Prevention, Therapy and Preparedness

Mirazimi, Alì; Weinbach, Jérôme; Weidmann, Manfred; Papa-Konidari, Anna; Leyssen, Peter; Korukluoğlu, Gülay; Weber, Friedemann

doi:10.1016/j.antiviral.2011.03.114

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drug T-705 or favipiravir selectively inhibits the replication of CCHFV and is a valid alternative for ribavirin in the treatment of CCHF. CCHF consortium supported the clinical use of favipiravir for treatment of CCHF (19).…”

Section: Resultsmentioning

confidence: 99%

A Systematic Review of Treatment Strategies Including Future Novel Therapies in Crimean-Congo Hemorrhagic Fever

Kouhpayeh

2021

Int J Infect

View full text Add to dashboard Cite

Introduction: Crimean-Congo hemorrhagic fever (CCHF) is an acute fetal illness the case fatality rate (CFR), which without treatment is between 26% to more than 80%. Despite the administration of ribavirin as a specific antiviral drug for the treatment of CCHF from many years ago, its clinical efficacy is still controversial. Objectives: This systematic review aimed to evaluate the clinical efficacy of ribavirin, favipiravir, and other treatment options for CCHF, including steroids, immunoglobulin, etc. Method: This systematic review included 31 articles, three factsheet from WHO, CDC, and ECDC, two editorial letters, and two textbooks from 2002 to 2020. The following databases were searched: Google Scholar, PubMed, Medscape, Cochrane, WHO, CDC, and ECDC. Results: The selected results of the above articles were concentrated on the different options of supportive treatment, including steroids, immunoglobulin, etc., as well as the efficacy of antiviral drugs, especially ribavirin and favipiravir. While some studies confirmed the clinical efficacy of ribavirin in the treatment of CCHF, some other studies did not confirm its efficacy. All studies justified that supportive therapies are the mainstay of treatment. Conclusions: The cornerstone of therapy of CCHF is supportive treatment. The clinical efficacy of ribavirin for CCHF treatment is questionable, and further randomized case-control clinical trials are required to confirm and recommend it for CCHF treatment. Also, other treatment strategies, including administration of steroids, immunoglobulin, and monoclonal antibodies (mAbs) require more conclusive data. The promising antiviral drug for CCHF treatment is favipiravir.

show abstract

Section: Resultsmentioning

confidence: 99%